• Explore /
  • Poster
  • / Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.

Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.

Abstract Poster

Authors

null

Jennifer Ann Wargo

The University of Texas MD Anderson Cancer Center, Houston, TX

Jennifer Ann Wargo , Rodabe Navroze Amaria , Merrick I. Ross , Robyn P.M. Saw , Jeffrey E. Gershenwald , Patrick Hwu , Sapna Pradyuman Patel , Isabella Claudia Glitza , Adi Diab , Richard Kefford , Richard A Scolyer , Helen Rizos , John F Thompson , Kerwin Shannon , Andrew Spillane , Matteo S. Carlino , Alex Guminski , Lauren Simpson , Michael A. Davies , Georgina V. Long

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Melanoma/Skin Cancers

Clinical Trial Registration Number

NCT01972347, NCT02231775

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS9091)

DOI

10.1200/jco.2015.33.15_suppl.tps9091

Abstract #

TPS9091

Poster Bd #

328a

Abstract Disclosures

Similar Posters

First Author: Jennifer Ann Wargo

First Author: Michael S. Gordon

First Author: Michael B. Atkins

Poster

2017 ASCO Annual Meeting

Preliminary results from the international neoadjuvant melanoma consortium (INMC).

Preliminary results from the international neoadjuvant melanoma consortium (INMC).

First Author: Alexander M. Menzies